Agree Peter.

You have a great weekend as well.

'Peter', it's coming soon. It's been way to quiet lately. It will happen when we least expect it.

Yep Peter, right on.

You have a good evening as well.

'Peter', ignore all this selling this time of year. I found out after many years of investing that December brings tax loss selling and nothing seems logical because of this.

I have made the most $$$ buying in December when they sell these kind of stocks for tax losses.

I just slowly add on the dips.

'Peter', I am using extreme patience here. I have never sold a single share of this company because I believe that PMCB and all the docs involved are on to something big and they know it. What I do is called investing. I have made the most $$$ investing this way.

I added 10,450 shares on the low today. If it keeps dropping I am going to purchase more. I currently own 330,000 shares after today's purchase and eventually I want to own 500,000 shares.

Agree 'Diaz83'.

~ Blue ~, it looks like it wants to take off today.

'Peter', yep and it's going up now.

Thanks Peter

'Peter', agree 100%. Patience is the key here.

'BioNewton', thanks for your knowledgeable post.

'Peter', when all this tax loss selling dries up this will start to go up.

~ Blue ~, agree.

~ Blue ~, I added more @ $0.2201 this am.

'naturalborninvestor', thanks.

'naturalborninvestor', the news you posted has been out for a while. Thanks for posting though.

Cetera Retail Brokerage is the money generator.

Beandog, that happened to me also. I bought @ .24 and it soon dropped. Happens every time.

I'm thinking a lot of this selling is tax loss selling and when the tax loss selling is over this will rise.

'Beandog', it can only go down $0.23 cents now.

'outnabout', agree. I bought 5,000 @ $0.24 today. It looks like the .24's are starting to dry up.

Blue, I bought back in yesterday and today. Currently own 10,000 shares @ an average of 0.2817.

My rational on this purchase was that if this company were going the BK route they would have done so by now before selling off divisions and hiring Lazard to explore options to raise additional capital and complete further asset divestitures.

'Peter', Happy Thanksgiving to you and all here on IH.

Great Peter, you too.

Peter. I purchased an additional 4,500 shares this am @ $0.09. I had another limit order in for another 28,500 shares @ $0.851 but I could not get a fill. I'm currently holding 304,500 shares @ an average of $0.1301 W/O commissions and $0.1334 with commissions added in.

The press release was very good news for the company but seems only us few longs believe in this company. I fully believe that this will virtually explode to the upside when it is least unexpected.

Peter, I was thinking the same thing about purchasing more shares tomorrow. I will have to watch how it trades. I added 39,000 shares from $0.096 to $0.10 this week. I purchased these right at the open of trading yesterday morning. I was surprised to see it go down after the EU orphan status news. Some must not understand what this news means for the company, but I do.

Peter, I fully agree with your post. I like to go in largely in companies that I know have huge potential. PMCB is one of them. I am planning on buying more if it gets into the mid eights. I would eventually like to own 500,000 shares. You have a great night.

Peter, I have never sold a share of PMCB. Today I'm holding 300,000 shares @ an average of $0.1340 with commissions added to the price paid. This company is on track to be a major player in cancer and diabetes treatments.

Countdown is finally over. Glad to be a long shareholder here holding 285,000 shares. GREAT news came out today.

Apollo Principal Holdings I, L.P. just issued a filing suggesting it has sold all of its RCS Capital Corporation

Apollo Principal Holdings I, L.P. recently filed a "Statement of acquisition of beneficial ownership by individuals" with the SEC in which it appears to no longer have any shares of RCS Capital Corporation.Previously it appears as though Apollo Principal Holdings I, L.P. owned as many as 5,000,000 shares. To see the most recent portfolio of Apollo Principal Holdings I, L.P. see here.

http://www.conferencecalltranscripts.org/13D/summary2/?id=2177656

RCS Capital Corporation director just declared ownership of no shares of RCS Capital Corporation

Michael William Conboy, a director of RCS Capital Corporation, appears to have filed an empty initial statement of beneficial ownership. This form is usually filed as a prelude to a company officer either receiving options or buying company shares, so there may be more to come from Conboy.

http://www.conferencecalltranscripts.org/5/summary/?id=2178503

Proxy Rigging Alleged at Schorsch-Linked Firm Before Apollo Deal
Bloomberg By Neil Weinberg, Prashant Gopal, Greg Farrell
1 hour ago

Thu, Nov 12, 2015, 8:13 PM EST - U.S. Markets closed

An arm of Nicholas Schorsch’s investment empire pressured employees into rigging shareholder proxy votes, Massachusetts’ securities regulator alleged in a complaint filed Thursday.

The complaint lays out allegations of a web of companies founded, created or partly owned by Schorsch -- alleging that employees of one of them, a Boston-based broker-dealer, impersonated shareholders in a bid to sway a proxy vote at another of the companies, an investment vehicle created by a firm that Schorsch co-founded.

As alleged, it’s a tale of subterfuge, fake accents and conflicting interests deep inside the world of real-estate finance. The twist is that its cast of characters is familiar: Many are among the companies that were part of a failed deal earlier this week that would have seen Apollo Global Management invest in two companies tied to Schorsch.

The failed deal, as proposed, involved the transfer of $19 billion in assets between the Schorsch-linked companies -- RCS Capital Corp. and AR Capital -- and New York-based Apollo.

Several of those companies figured in the narrative laid out in Thursday’s administrative complaint filed by Massachusetts’ Secretary of the Commonwealth, William Galvin.

At its center is a specialty finance company called Business Development Corp. of America, which the complaint said was sponsored by American Realty Capital, or AR Capital, a closely held company founded and part-owned by Schorsch.

Shareholders of BDCA were asked in September to vote in favor of several changes to the company’s charter, according to the complaint. Those changes were a prerequisite for the proposed deal with Apollo, the complaint said.

More from Bloomberg.com: Six Strange Things That Have Been Happening in Financial Markets

‘Contrived’ Accents

To lock in the vote, employees of a Boston-based company also linked to Schorsch -- Realty Capital Securities LLC, a subsidiary of RCS Capital -- fabricated proxy votes, the complaint alleged. Posing as shareholders, the employees at times adopted “contrived” accents to fool a proxy company into accepting the votes, it said.

The Massachusetts complaint accuses Realty Capital Securities of proxy-voting fraud and seeks to revoke its broker-dealer registration in the state.

A representative for Realty Capital Securities didn’t immediately respond to a request for comment.

Galvin, in an announcement of his action, mentions the Apollo deal but doesn’t address whether its failure may have been linked to the allegations of vote-rigging. The complaint doesn’t accuse AR Capital, RCS Capital or Apollo of wrongdoing.

More from Bloomberg.com: Rolls-Royce Lays Bare Entrenched Failings to Stunned Investors

A representative of AR Capital didn’t immediately respond to a request for comment. Apollo Global Management declined to comment through Charles Zehren of Rubenstein Associates.

Reviewing Complaint

RCS Capital, in a statement, said it is reviewing the complaint and is fully cooperating with all relevant agencies. It declined to comment further.

Schorsch wasn’t made available to respond to requests for comment placed with representatives for AR Capital and RCS Capital.

The Massachusetts action is the latest to touch a network of companies linked to Schorsch, who resigned from boards of several of them last year after one of his real estate investment trusts disclosed that it had accounting errors that were intentionally concealed. AR Capital said at the time that the moves would elimate any perceived conflicts, with Schorsch, expressing faith in the directors, saying the changes were part of the natural evolution of the growing companies.

Closely held AR Capital has created non-traded REITs and then generated fees by serving as their external managers. Schorsch was the biggest shareholder of RCS Capital -- whose businesses include raising money from investors for AR Capital nontraded REITs -- as of Oct. 14, according to data compiled by Bloomberg. He resigned from its board at the end of 2014, according to a regulatory filing.

Fee of $375,000

Before the Apollo deal could happen, according to the Massachusetts complaint, shareholders of Business Development Corp. of America would have to approve nine changes -- which an employee cited in the complaint characterized to state investigators as “less shareholder friendly”-- to the company charter.

That’s where Realty Capital Securities, the Boston-based subsidiary of RCS Capital, allegedly came in.

Apollo and AR Capital paid approximately $375,000 to RCS and a related company for “proxy solicitation services,” the complaint alleges. That payment was made “notwithstanding the inherent conflict with the brokerage firm’s vested interest in reaching an affirmative vote,” Galvin’s office said in a statement announcing its action.

Poor Optics

“The optics of using an affiliated proxy solicitation firm are not good,” said Kevin Gannon, chairman and chief executive officer of Robert A. Stanger & Co., a Shrewsbury, New Jersey-based investment bank. “It’s pretty ugly.”

RCS exerted “immense internal pressure” to round up votes, according to the complaint, including in the form of an Aug. 5 e-mail from a senior RCS officer.

“We need each and everyone of you regardless of excuse and circumstance to focus on this all day today...this...is for your own personal well-being,” the manager wrote, according to the complaint. “Please don’t put me in a position where I’m asking you why you are not working on Proxy.”

Risk Termination

Employees were also told that if they didn’t participate in the proxies, they would get a call from Michael Weil and would risk termination, the complaint said. Weil is chairman of RCS and AR Capital’s president and chief operating officer, according to the complaint.

Representatives for the companies didn’t respond to requests to make Weil available for interview.

As part of the alleged scheme, RCS employees called a proxy firm, claiming to have located BDCA shareholders, and conferenced in colleagues who in at least two instances impersonated shareholders, according to the complaint. One RCS employee, adopting an accent, allegedly told the proxy-solicitation firm representative that he was voting with BDCA’s management and directors on all proposals.

Some of this information was provided by a “concerned” employee, said the complaint.

Mutual Withdrawal

Apollo and investment-management firm AR Capital mutually agreed on Nov. 9 to cancel a transaction in which a new company, AR Global Investments, would have absorbed about $19 billion overseen by Schorsch, with Apollo holding a 60 percent stake in AR Global. RCS Capital’s shares fell 46 percent that day.

As part of the termination of the deal, AR Capital is purchasing from Apollo $25 million of RCS Capital preferred stock for $25.6 million, according to a statement.

More from Bloomberg.com

http://finance.yahoo.com/news/proxy-rigging-alleged-schorsch-linked-235410815.html

Massachusetts regulator charges RCS Capital unit with proxy voting fraud

Thu, Nov 12, 2015, 2:01pm EST

(Adds details on allegations, firm ownership)

By Ross Kerber

BOSTON, Nov 12 (Reuters) - Massachusetts' top securities regulator on Thursday charged a unit of RCS Capital Corp with fraudulently casting shareholder proxy votes, alleging fake accents were used to impersonate investors.

An administrative complaint filed by Massachusetts Secretary of the Commonwealth William Galvin seeks penalties including a fine and the revocation of the broker-dealer registration of Realty Capital Securities, a Boston subsidiary of brokerage holding company RCS Capital.

A spokesman for the companies did not return messages.

Galvin's complaint states his investigation identified at least two cases of fabricated proxy votes concerning Business Development Corporation of America, an American Realty Capital-sponsored investment fund.

RCS Capital's former executive chairman, the well-known real estate investor Nicholas Schorsch, resigned last year. Schorsch also stepped down in December as executive chairman of American Realty Capital Partners, a real estate investment trust. Earlier this year it restated financial results after discovering intentional accounting errors. (http://reut.rs/1M9DxZ2)

In two instances, the complaint states, people who worked for Realty Capital "used a contrived accent" to impersonate shareholders and to cast proxy votes in favor of the fund's management, once at the fund's annual meeting and a second time at a special meeting.

Galvin's office said it obtained audio recordings of the votes being cast.

The complaint states investigators believe the voting irregularities were much more widespread than those two votes. Employees at Realty Capital, "facing intense pressure from management, replicated this fraudulent action over numerous proxy votes," the complaint states.

The case arose from information provided by an employee of Realty Capital, Galvin's office said.

(Reporting by Ross Kerber; Editing by Chizu Nomiyama, Bernard Orr)

http://finance.yahoo.com/news/massachusetts-regulator-charges-rcs-capital-181938372.html

BioNewton, well said post.

Questions Answered About the New PharmaCyte Biotech Pancreatic Cancer Trial Design
PharmaCyte Biotech Inc. (OTCMKTS:PMCB) has been a busy beaver lately, perhaps even leaving some investors confused. Thanks to this interview, all of a sudden it all makes sense.

By James E. Brumley
Oct 23, 2015 7:16:25 AM PDT | No Comment(s) - Post a Comment Rating

Investors who've been following the PharmaCyte Biotech Inc. (OTCMKTS:PMCB) story closely of late will have noticed a flurry of news releases posted over the past week and a half, all of which pointed to a change in the direction that its primary drug trial was taking. The sheer number of press releases from PMCB, though (and their scope), may have been overwhelming... an understandable outcome considering what was at hand. Any clinical trial is going to be a complex issue, and when a trial's design is completely redesigned, a lot of details need to be hashed out again.

And in this particular case, it was an especially tough change to get a grip on, as the biotechnology being tested itself was brand new, and its target ailment - pancreatic cancer - remains an underserved and underwatched one. But, between the company's past three news releases, the data and information regarding the reconfigured trial is there. You just have to ferret it out.

Or, you could just listen to this recent interview of CEO Kenneth L. Waggoner and COO Dr. Gerald W. Crabtree, in which the two gentleman leading the company and ultimately initiating the trial's design explain in plain English exactly what the new trial is, why it's important, and what the endpoint goals for the new trail are.

It's admittedly been a whirlwind for PMCB in just the past few days, with the news - and the meaning of the news - tough to get a bead on. But, in the interview, all the heavy details and changes that may have been tough to follow up until this point are clarified.

As for investors who have never heard of PharmaCyte Biotech and are unfamiliar with its work to date, it's actually a quite compelling story.

he technology is called Cell-in-a-Box(r). In simplest terms, PharmaCyte Biotech has developed Cell-in-a-Box(r) as a means of encapsulating and implanting living cells into a patient's body where they can drive a specific therapeutic effect. In the case of PharmaCyte's pancreatic cancer therapy, these encapsulations (about the size of the head of a pin) contain about 10,000 live cells each that produce an enzyme that catalyzes a cancer-fighting drug called ifosfamide.

The advantage to such an approach is pinpoint placement within the human anatomy. The Cell-in-a-Box(r) encapsulations -- about 300 of them - are placed as closely to the pancreatic tumor as possible. This is done by threading a catheter up through an artery in the leg leading to the pancreas. When the catheter is in place, the capsules are injected through the catheter and placed at or near the tumor in the pancreas. After they are placed, then low-doses of ifosfamide are given to the patient intravenously. This method of delivery allows for maximum drug efficacy with only one-third the normal dosage of ifosfamide, and there is little to no drug "loss" in the wrong parts of the body.

And make no mistake -- the need for such a solution is tremendous.

As Dr. Lohr pointed out, of the 80% of pancreatic cancer patients who don't have the option of surgical removal, about half of them are proverbially trapped in the middle because their tumor is neither growing nor shrinking and surgery isn't possible. They'll simply be forced to live with a pancreatic tumor, hoping it doesn't metastasize, remaining on a drug regimen with just so-so effectiveness controlling the disease. Sooner or later, though, it does metastasize. Beating it is always the better option, if possible.

It's this sizeable segment of the pancreatic cancer patient pool where PharmaCyte Biotech is poised to bring hope by bringing a superior treatment to the market. Now, between Friday's interview and the recent press releases, it's crystal clear exactly which pancreatic cancer patients PMCB is aiming to serve. And, as it turns out, it's a big swath that's not directly being addressed by anyone, or any one drug specifically designed to deal with their unique condition... inoperable pancreatic tumors that no longer respond to front-line treatments.

The interview explains it all.

http://www.smallcapnetwork.com/Questions-Answered-About-the-New-PharmaCyte-Biotech-Pancreatic-Cancer-Trial-Design/s/via/10/article/view/p/mid/1/id/546/

Will do PP, you do the same.

Congrats, GREAT average '$Pistol Pete$'. Wish mine was that low. When the important news comes out my average will be peanuts.

'$Pistol Pete$'. I added 18,500 shares to my existing position this week.

I am really gettig the gut feeling that very important great news is coming soon. My mind keeps telling me to be adding here now because when the news comes out one morning a person will not be able to buy quick enough.

Average on 261,000 shares = $0.1464 without commissions and $0.15 with commissions included.

Wishing you a great weekend PP,

'$Pistol Pete$', agree, it's coming soon.

'Solarman', me to. When this happens all the bashing this company will come to an abrupt end.

Thanks, OptimusPrime, I will be watching.

Yep, thanks, 'Johnnycash2013', I'll be watching.